Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Non-cash Items (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Non-cash Items for 2 consecutive years, with $7.5 million as the latest value for Q4 2025.

  • Quarterly Non-cash Items rose 7400.0% to $7.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.5 million through Dec 2025, up 7400.0% year-over-year, with the annual reading at $7.5 million for FY2025, 7400.0% up from the prior year.
  • Non-cash Items hit $7.5 million in Q4 2025 for Prelude Therapeutics, up from $1.1 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $8.1 million in Q3 2024 to a low of $6000.0 in Q1 2025.